BD

ZK SEPARATION: Pioneering Excellence in Decanter Tech for Food and Water Industry

Retrieved on: 
Tuesday, October 24, 2023
Water, Food safety, Sanitation, Decanter centrifuge, Lubricant, Hope, Foodservice, Maintenance, BD, CIP, ZK, Dry, Drink, Safety, Sewage treatment, Bottled water, Asset management, Food

CHENGDU, China, Oct. 24, 2023 /PRNewswire-PRWeb/ -- In the relentless pursuit of precision and performance, ZK SEPARATION has carved a distinctive niche for itself as a beacon of innovation and sustainability. Their impressive portfolio includes over 110 patents and a global presence in more than 30 countries. With an annual delivery of over 400 units and involvement in more than 300 projects, ZK SEPARATION is revolutionizing the realms of Food & Beverage and Water Treatment through their advanced Decanter Centrifuge technology.

Key Points: 
  • ZK SEPARATION: Revolutionizing the Food & Water Industry with Decanter Centrifuge Tech.
  • ZK SEPARATION's Decanter Centrifuges have proven their value by offering an array of advantages that set new industry standards.
  • ZK SEPARATION's journey in the Food & Beverage and Water Treatment sectors is a testament to their unwavering commitment to excellence.
  • ZK SEPARATION – where innovation, excellence, and sustainability converge to shape a better future for Food & Beverage and Water Treatment industries.

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

Retrieved on: 
Monday, October 23, 2023
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Lithium, Post-traumatic stress disorder, MTD, Trial of the century, IND, MDD, Food, Clinical research associate, Depression, Bipolar disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cyclothymia, BD, Index, Brain, NDA, Safety, IIA, Patient, TDM, Communication, Lithium toxicity, Pharmaceutical industry, Medical device

Although the ideal role for lithium augmentation has yet to be established, there is evidence to support the clinical practice of adding lithium to conventional antidepressants in pursuit of MDD remission.

Key Points: 
  • Although the ideal role for lithium augmentation has yet to be established, there is evidence to support the clinical practice of adding lithium to conventional antidepressants in pursuit of MDD remission.
  • AL001 is a novel lithium-delivery system that has the potential to provide benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium.
  • “This IND submission represents the next key milestone for Alzamend as we further advance our proprietary pipeline,” said Stephan Jackman, Chief Executive Officer of Alzamend.
  • We look forward to providing more details regarding the study’s timeline and market opportunity in the near future.”

Global Syringes & Needles Market Soars with a Strong 7.93% CAGR, Expected to Reach $47.20 Billion by 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 20, 2023
Medical Supplies, Health, Ageing, Cardinal Health, Prevalence, Conditional sentence, Diabetes, BD, Syringe, Injury, Growth, Hospital, Needle, Beauty salon, Dentistry

The global syringes & needles market is experiencing robust growth, with a projected CAGR of 7.93% from 2023 to 2029.

Key Points: 
  • The global syringes & needles market is experiencing robust growth, with a projected CAGR of 7.93% from 2023 to 2029.
  • The market, valued at $29.85 billion in 2023, is expected to reach $47.20 billion by 2029.
  • Several key factors are driving this growth, while the market is also influenced by regional dynamics and market segmentation.
  • Leading players dominating the global syringes & needles market include BD, Cardinal Health, B Braun, Nipro, and Terumo Corp.

Deepcoin Exhibits at Future Blockchain Summit & Hosts Grand Party Event in Dubai

Retrieved on: 
Monday, October 23, 2023
Crypto, Exhibition, Web3, Social media, Mass media in China, Heart, Investment, Business development, News, GITEX, Research, BD, Environment, Ecosystem, Partnership, Mała Panew, Web 3.0, Cryptocurrency, NFT, MENA, Blockchain, Chinese, Metaverse

The Future Blockchain Summit, an event at GITEX and hailed as the MENA region's most immersive large-scale blockchain event, has been revamped to embolden disruptors, empower change-makers, and inspire innovators in the realms of Web 3.0, Blockchain, Crypto, NFT, Metaverse, and Gaming.

Key Points: 
  • The Future Blockchain Summit, an event at GITEX and hailed as the MENA region's most immersive large-scale blockchain event, has been revamped to embolden disruptors, empower change-makers, and inspire innovators in the realms of Web 3.0, Blockchain, Crypto, NFT, Metaverse, and Gaming.
  • Deepcoin's active participation in the prestigious Future Blockchain Summit reflects its steadfast commitment to revolutionizing the cryptocurrency and blockchain industry.
  • Visitors to Deepcoin's booth at the Future Blockchain Summit welcomed anyone where they can engage directly with the Deepcoin team.
  • Deepcoin's presence at the Future Blockchain Summit also underscored its commitment to fostering innovation and collaboration within the crypto space.

BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER

Retrieved on: 
Thursday, October 19, 2023
Applied Biosystems, Risk, ACD, Security (finance), Development, Therapy, Vaccine, Bio-Techne, Biotechnology, Pathology, Affymetrix, Research, Software, BD, Growth, Biology, Marketing, Annual report, Retirement, Thermo Fisher Scientific, Sustainability Accounting Standards Board, Diagnosis, BD (company), Senior advisor, DGS, Management

MINNEAPOLIS, Oct. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer effective February 1, 2024.

Key Points: 
  • MINNEAPOLIS, Oct. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer effective February 1, 2024.
  • Prior to assuming CEO responsibilities, Mr. Kelderman will become Chief Operating Officer (COO) effective November 1, 2023, where he will be responsible for the day-to-day operations of the Company.
  • Mr. Kelderman succeeds Chuck Kummeth, who will be retiring from the company after serving as President, Chief Executive Officer and Board Director for the past 10 years.
  • "Kim is the ideal candidate to lead Bio-Techne during the Company's next stage of growth," said Chuck Kummeth, Bio-Techne's President and Chief Executive Officer.

BD Named Among the 100 Best Corporate Citizens of 2023

Retrieved on: 
Wednesday, October 18, 2023
Becton, NYSE, ESG, Sustainable Development Goals, History, Paris, Workforce, Responsibility, BD, Environment, BDX, Human rights, Health equity, Paris Agreement, Becton, Dickinson and Company headquarters, Climate change, Management

FRANKLIN LAKES, N.J., Oct. 18, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named to the 100 Best Corporate Citizens List by 3BL, which recognizes outstanding environmental, social and governance (ESG) transparency and performance among 1,000 of the largest U.S. public companies. This year, BD ranked second in the health care equipment and services industry.

Key Points: 
  • FRANKLIN LAKES, N.J., Oct. 18, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named to the 100 Best Corporate Citizens List by 3BL, which recognizes outstanding environmental, social and governance (ESG) transparency and performance among 1,000 of the largest U.S. public companies.
  • This year, BD ranked second in the health care equipment and services industry.
  • The 100 Best Corporate Citizens ranking is based on 184 ESG factors in seven pillars – climate change, employee relations, environment, governance, human rights, stakeholders and society, and ESG performance.
  • The 100 Best Corporate Citizens of 2023 are answering the call by demonstrating the societal and bottom-line value of leadership and transparency around ESG topics.

AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Cancer, MBA, NYSE, Doctor of Philosophy, Viral, MD, BD, DSM-IV codes, AIM, Malignancy, Sales

Azenova has been engaged to assist AIM with its BD efforts with the goal of entering into a partnership, out-license or other transaction whereby a biopharmaceutical company takes on the further development and commercialization of Ampligen® with the goal of maximizing value to AIM.

Key Points: 
  • Azenova has been engaged to assist AIM with its BD efforts with the goal of entering into a partnership, out-license or other transaction whereby a biopharmaceutical company takes on the further development and commercialization of Ampligen® with the goal of maximizing value to AIM.
  • This process may not result in any transaction and the company does not intend to disclose additional details unless and until it has entered into a definitive agreement.
  • Azenova provides a wide range of services to support clients in their partnership, licensing, and other transactional activities.
  • This includes determining opportunities for partnership (assets and technologies), identification and assessment of potential partners and leading all steps involved in engaging partners and establishing definitive BD transaction agreements.

United States Cardiovascular Needle Market Insights and Forecast Report, 2022-2023 & 2026 - AI is Making Inroads in Cardiovascular Medicine, Improving Prognosis and Treatment Outcomes - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Health, Cardiology, Diagnosis, Cardiovascular disease, Nursing care plan, Infection, COVID-19, Disease, Injury, Becton, Dickinson and Company headquarters, Bleeding, Brain, Prevalence, Blunt cardiac injury, Artificial intelligence, AI, Risk, Heart, Mortality, Becton, Splenic infarction, Medtronic, BD, Type, Gesellschaft mit beschränkter Haftung, CVD, Society, Blood, Johns Hopkins, Growth, Surgical suture, ICU, Disorder, Tissue, Hospital, FSSB, Skin, Stroke, Needle, Prognosis, Birth, Patient, Surgeon, Fatality, Beauty salon, Pharmaceutical industry, Medical device, Silk

The US cardiovascular needle market is foreseen to reach US$36.71 million in 2023, growing at a CAGR of 7.55% during the forecasted period.

Key Points: 
  • The US cardiovascular needle market is foreseen to reach US$36.71 million in 2023, growing at a CAGR of 7.55% during the forecasted period.
  • The treatment of these disorders often requires specialized surgeries, during which cardiovascular needles are used to suture the wounds.
  • Consequently, the increasing prevalence of cardiovascular diseases has driven the demand for cardiovascular devices for diagnosis and treatment, contributing to the growth of the cardiovascular needle market in recent years.
  • Artificial intelligence (AI) is making inroads in cardiovascular medicine, improving prognosis and treatment outcomes.

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Retrieved on: 
Tuesday, October 17, 2023
BDX, NYSE, Becton, Dickinson and Company headquarters, PepsiCo, General Electric Company, Treasury, Terex, Becton, BD, Growth, Management, Boston College, Science

FRANKLIN LAKES, N.J., Oct. 17, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately.

Key Points: 
  • FRANKLIN LAKES, N.J., Oct. 17, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately.
  • Rodetis will continue to report to Chris DelOrefice, executive vice president and chief financial officer for BD.
  • Rodetis joined BD in 2016 as vice president and assistant treasurer, capital markets.
  • Prior to BD, Greg was with Terex Corporation as the assistant treasurer and prior to this he held roles of progressive responsibility with PepsiCo, Inc., and General Electric Company.

BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices

Retrieved on: 
Monday, October 16, 2023
Health, Hospital, BDX, Recycling, NYSE, Becton, Dickinson and Company headquarters, ESG, Casella Waste Systems, Municipal solid waste, State, Becton, BD, Syringe, Medical device, Biodegradable waste, Needle, Plastic, Casella

FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 (GLOBE NEWSWIRE) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Casella Waste Systems, Inc. (Nasdaq: CWST) (Casella), a solid waste, recycling, and resource management services company, today announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.

Key Points: 
  • The medical waste was collected across a variety of health care facilities and all of the plastics were diverted from disposal and recycled.
  • The pilot also assessed technical feasibility of two types of technology – mechanical and advanced recycling – both showing favorable results in their ability to successfully recycle used medical devices for use in other products.
  • The teams will also increase focus to cover other types of medical materials for recycling, as well as reclaiming the used devices and returning them to the manufacturing process.
  • “This pilot showcases the strength of collaborative partnerships when it comes to sustainable material management practices,” said Casella Chairman and CEO, John W. Casella.